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INTRODUCTION
Nanoparticulate  drug  delivery  systems  (DDS)  have  attracted  a  lot  of
attention  because  of  their  size-dependent  properties.  Among  the  array  of
nanoparticles  being  currently  investigated  by  pharmaceutical  scientists,  lipid
nanoparticles have taken the lead because of obvious advantages of higher degree
of  biocompatibility  and  versatility.  These  systems  are  commercially  viable  to
formulate pharmaceuticals for topical, oral, pulmonary or parenteral delivery. 
Lipid nano formulations can be tailored to meet a wide range of product
requirements  dictated  by  disease  condition,  route  of  administration  and
considerations of cost, product stability, toxicity and efficacy. The proven safety
and  efficacy  of  lipid-based  carriers  make  them  attractive  candidates  for  the
formulation  of  pharmaceuticals,  as  well  as  vaccines,  diagnostics  and
nutraceuticals.1 The  most  frequent  role  of  lipid-based  formulations  has
traditionally  been  to  improve  the  solubility  of  sparingly  water  soluble  drugs
especially Biopharmaceutics Classification System (BCS) Classes II & IV drugs.
However, the spectrum of applications for lipid-based formulations has widened as
the nature and type of active drugs under investigation vary. 
Lipid-based  formulations  may  also  protect  active  compounds  from
biological degradation or transformation that in turn can lead to an enhancement of
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drug potency. In addition, lipid-based particulate DDS have been shown to reduce
the toxicity of various drugs by changing the bio-distribution of the drug away
from sensitive organs. This reduction in toxicity may allow for more drug to be
administered and forms the basis for the current success of several marketed lipid-
based formulations of amphotericin B (Ambisome®, Abelcet®) and doxorubicin
(Doxil®, Myocet®)1.  Rapid advances in the ability to produce nanoparticles of
uniform size,  shape, and composition have started a revolution in science. The
development of lipid-based drug carriers has attracted increased attention over the
last decade.
 Lipid  nanoparticles  (e.g.  solid  lipid  nanoparticles,  SLNs)  are  at  the
forefront of the rapidly developing field of nanotechnology with several potential
applications in drug delivery, clinical medicine and research, as well as in other
varied sciences. Due to their size-dependent properties, lipid nanoparticles offer
the possibility to develop new therapeutics that could be used for secondary and
tertiary level of drug targeting. Hence, lipid nanoparticles hold great promise for
reaching the goal of controlled and site specific drug delivery and have attracted
wide attention of researchers. 
At the turn of the millennium, modifications of SLN, nanostructured lipid
carriers (NLC) and lipid drug conjugate (LDC)-nanoparticles were introduced2,3 in
addition  to  liquid  crystal  DDS.  These  carrier  systems  overcome  observed
limitations  of  conventional  SLN  and  more  fluid  lipid  DDS.  Compared  to
2
  
liposomes and emulsions, solid particles possess some advantages, e.g. protection
of  incorporated  active  compounds  against  chemical  degradation  and  more
flexibility in modulating the release of the compound. This paper focuses on the
different lipid based nano systems, their structure and associated features, stability,
production  methods,  drug  incorporation  and  other  issues  related  to  their
formulation  and use  in  drug  delivery.  The following advantages  among others
could be ascribed to lipid based nanocarriers:
• Ability to control and target drug release.
• Ability to improve stability of pharmaceuticals.
• Ability to encapsulate high drug content (compared to other carrier systems
e.g. polymeric nanoparticles).
• The feasibility of carrying both lipophilic and hydrophilic drugs.
• Most of the lipids used are biodegradable, and as such they have excellent
biocompatibility, are non-toxic, non-allergenic and non-irritating.
• They can be formulated by water-based technologies and thus can avoid
organic solvents.
• They are easy to scale-up and sterilize.
• They are less expensive than polymeric/surfactant based carriers.
• They are easy to validate.
Drug delivery systems
A drug delivery system is defined as a formulation or a device that enables
the introduction of a therapeutic substance in the body and improves its efficacy
3
  
and safety by controlling the rate, time, and place of release of drugs in the body.
The  process  of  drug  delivery  includes  the  administration  of  the  therapeutic
product, the release of the active ingredients by the product, and the subsequent
transport of the active ingredients across the biological membranes to the site of
action. DDS interface between the patient and the drug. It may be a formulation of
the drug or a device used to deliver the drug4.
Lipids
The carboxylic acid group of a fatty acid molecule provides a convenient
place for linking the fatty acid to an alcohol, via an ester linkage. If the fatty acid
becomes attached to an alcohol with a long carbon chain, the resultant substance is
called a wax. When glycerol and a fatty acid molecule are combined, the fatty acid
portion of the resultant compound is called an acyl group, and the glycerol portion
is referred to as a glyceride. A triacylglyceride thus has three fatty acids attached
to a single glycerol molecule. Sometimes, this name is shortened to triglyceride.
Triglyceride substances are commonly referred to as fats or oils,  depending on
whether they are solid or liquid at room temperature 5. 
A lipid is thus a fatty or waxy organic compound that is readily soluble in
non-polar solvents (e.g. ether), but not in polar solvent (e.g. water). Examples of
lipids  are waxes,  oils,  sterols,  cholesterol,  fatsoluble vitamins,  monoglycerides,
diglycerides,  triglycerides (fats),  and phospholipids.  Fatty acids (including fats)
are  a  subgroup  of  lipids,  hence,  it  will  be  inaccurate  to  consider  the  terms
synonymous.
4
  
Lipid drug delivery systems
Lipid-based DDS are an accepted, proven, commercially viable strategy to
formulate  pharmaceuticals  for  topical,  oral,  pulmonary  or  parenteral  delivery.
Lipid formulations can be tailored to meet a wide range of product requirements.
One  of  the  earliest  lipid  DDS  liposomes  have  been  used  to  improve  drug
solubility. Currently,  some companies have established manufacturing processes
for the preparation of large scale batches of sparingly soluble compounds, often at
drug concentrations several orders of magnitude higher than the nominal aqueous
solubility because of the introduction of novel lipid-based DDS1.
Lipid nanoparticulate drug delivery systems
Lipid  nanoparticles  show  interesting  nanoscale  properties  necessary  for
therapeutic application. Lipid nanoparticles are attractive for medical purposes due
to their important and unique features, such as their surface to mass ratio that is
much larger than that of other colloidal particles and their ability to bind or adsorb
and carry other compounds. Lipid nano formulations produce fine dispersions of
poorly water soluble drugs and can reduce the inherent limitations of slow and
incomplete dissolution of poorly water soluble drugs (e.g. BCS II & IV drugs),
and facilitate formation of solubilised phases from which drug absorption occurs. 
In  any  vehicle  mediated  delivery  system  (whether  the  vehicle  is  an
emulsion, liposome, noisome or other lipidic systems), the rate and mode of drug
5
  
release from the system is important in relation to the movement of the delivery
system in vivo. Lipid particulate DDS abound depending on their architecture and
particle size.  Due to the large number of administration routes available,  these
delivery systems perform differently depending on the formulation type and route
of administration. Some of the different lipid particulate DDS are shown in Figure
1.
Figure 1. Lipid particulate drug delivery systems
Nanoparticle drug delivery systems are a promising avenue in the field of
targeted drug delivery for the treatment of various diseases. The application of this
technology  improves  the  bioavailability,  physico-chemical  stability,  and  drug
loading  efficiency.  Surface  coating,  nanoparticle  fabrication,  fundamental
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composition,  and  drug  loading  are  critical  factors  that  need  to  be  considered
during drug design. Examples of this delivery system were successfully employed
in the field of brain, cosmetic, dermal, bone fracture, and cancer target deliveries.6
To overcome hepatic first-pass metabolism and to enhance bioavailability,
intestinal  lymphatic  transport  of  drugs  can  be  exploited.  Transport  of  drugs
through  the  intestinal  lymphatics  via  the  thoracic  lymph  duct  to  the  systemic
circulation  at  the  junction  of  the  jugular  and  left  subclavian  vein,  avoids
presystemic  hepatic  metabolism and  therefore  enhances  bioavailability.  Highly
lipophilic compounds such as long-chain triglycerides reach systemic circulation
via the lymphatics.7Nanoparticles coated with hydrophobic polymers tend to be
easily  captured  by  lymphatic  cells  in  the  body.  Intraduodenally  administered
tobramycin-loaded SLN showed sustained release and lymphatic targeting. 
 Lipid-based  drug  delivery  systems  may  contain  a  broad  range  of  oils,
surfactants, and co-solvents. They represent one of the most popular approaches to
overcome  the  absorption  barriers  and  to  improve  the  bioavailability  of  poorly
water-soluble drugs. Furthermore, among the factors affecting the bioavailability
of  the  drug from lipid-based formulations  are the  digestion of  lipid,  the  mean
emulsion droplet  diameter,  the lipophilicity of  the  drug and the type  of  lipids.
Lipid  formulations  can  reduce  the  inherent  limitation  of  slow and  incomplete
dissolution of poorly water-soluble drugs and facilitate formation of solubilized
phases from which absorption may occur. The solubilized phases most likely arise
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from  intral  aminal  processing  after  lipid  absorption.  The  co-administration  of
lipids with drugs can also impact their absorption pathway although most orally
administered  compounds  gain  access  to  the  systemic  circulation via  the  portal
vein,  some  highly  lipophilic  drugs  are  transported  directly  to  the  systemic
circulation via intestinal lymphatic’s, which improves oral bioavailability of API.8
Nanoparticles
Nanoparticles  are  solid  polymeric,  submicronic  colloidal  system  range
between 5-300nm consisting of macromolecular substances that vary in size 10nm
to  1000nm.  The  drug  of  interest  is  dissolved,  entrapped  adsorbed,  attached  or
encapsulated  into  the  nanoparticles  matrix.  Depending  upon  the  method  of
preparation,  nanoparticle,  nanosphere  or  nanocapsule  can  be  obtained  with
different  properties  and  release  characteristics  for  the  encapsulated  therapeutic
agent. Nanosphere are matrix system in which drug is physically and uniformly
dispersed throughout, then particles prepared by using different polymers such as
polyalkyl cyano-acrylate & poly lactides or they can be solid lipid nanosphere
prepared using lipids like  dipalmitoyl  –  phosphatidyl  choline.  Nanocapsule are
ultrafine vesicular system with a diameter less than 1 mcm in which the drug is
confined  to  a  cavity  surrounded  by  a  unique  polymer  membrane  and  having
aqueous or oily core containing drug substances. 9
Nanoparticles holds much interest, because in this range materials can have
different and enhanced properties compared with the same materials of a larger
8
  
size due to the following two major principle factors. The increased surfaces are of
quantum effect. These factors can enhance properties such as reactivity, strength,
electrical characteristics & in vivo behavior and a much greater surface area per
unit  mass  compared  with  the  larger  particles  leading  to  greater  reactivity.  The
advantages of using nano particles for nanoparticles loaded with drugs, because of
their small size can penetrate through small capillaries and are taken up by cells
and allow the drug release at right rate and dose at specific sites in the body for a
certain time to release the accurate delivery, which enhances the therapeutic effect
and reduces the toxicity and side effects. The use of biodegradable materials for
nanoparticles  preparation  allows sustained release  within  the  target  site  over  a
period of days or even weeks.
Types of NPS as carrier for drug & diagnostic agents
• Polymeric NPS
• Nanosuspensions and nanocrystals
• Polymeric micelles
• Ceramic NPS
• Liposomes
• Fullerenes and dendrimers
• SLNP (Solid lipid nanoparticles)
• Magnetic nanoparticles
• Nanoshells coated with gold
• Nanomers and carbon nanotubes10
Solid lipid nanoparticles (SLN)
SLN  are  particulates  structurally  related  to  polymeric  nanoparticles.
However,  in  contrast  to  polymeric  systems,  SLN  can  be  composed  of
9
  
biocompatible lipids that are physiologically well tolerated when administered in
vivo and may also be prepared without organic solvents. The lipid matrices can be
composed  of  fats  or  waxes  (homolipids)  that  provide  protection  to  the
incorporated  bioactive  from chemical  and  physical  degradation,  in  addition  to
modification of drug release profile.  Typical  formulations utilize lipids such as
paraffin  wax  or  biodegradable  glycerides  (e.g.  Compritol  888  ATO)  as  the
structural base of the particle11. 
SLN were developed in the 1990s as an alternative carrier system to the
existing  traditional  carriers,  such  as  emulsions,  liposomes  and  polymeric
nanoparticles.  SLN are  prepared either  with  physiological  lipids  or lipids  with
generally regarded as safe (GRAS) status. Under optimized conditions they can
incorporate lipophilic or hydrophilic drugs and seem to fulfil the requirements for
an optimum particulate carrier system12.  SLN have a potential wide application
spectrum-  parenteral  administration  and  brain  delivery,  ocular  delivery,  rectal
delivery,  oral  delivery,  topical  delivery  and  vaccine  delivery  systems  etc.,  in
addition to improved bioavailability, protection of sensitive drug molecules from
the  outer  environment  and  even  controlled  release  characteristics.  Common
disadvantages  of  SLN  are  particle  growth,  unpredictable  gelation  tendency,
unexpected dynamics of polymorphic transitions and inherent low incorporation
rate due to the crystalline structure of the solid lipid13.
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LITERATURE REVIEW
1. Muller RH et al., studied the solid Lipid nanoparticles (SLN) and nano
structured lipid carriers (NLC) in cosmetic and dermatological preparations
and reported the involvement and improvement of the delivery of cosmetic
preparations when it’s delivered in the form of solid lipid nanoparticles.
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2. Muller  RH  et  al., studied  the  medicament  vehicle  for  the  controlled
administration of an active agent, produced from lipid matrix-medicament
conjugates.  They reported  the  delivery of  medicament  conjugate  and its
advantage when it was delivered in the lipid matrix.
3. Goswami  S  et  al., reviewed  lovastatin  and  its  production.  The
biotechnological production of lovastatin and its simplicity in production
was reviewed. The lipid lowering drug lovastatin acting on the HMG-Co A
and its production was done and isolation and purification was discussed.
The review also deals with the structure, properties, biosynthetic pathway,
submerged fermentation, applications and side effects of lovastatin.
4. Jawahar N  et  al., solid  lipid  nanoparticles  for  oral  delivery  of  poorly
soluble  drugs.  They reported  the  advantages  and  disadvantages  of  solid
lipid  nanoparticles.  Various  methods  of  preparation of  nanoparticles  and
their evaluation were also reported. They also reported the applications of
nanoparticles in pharmaceutical field.  They discussed the physico-chemical
properties of  solid lipid nanoparticles, Lymphatic mechanism, production
methods, in-vivo fate of lipids and potential therapeutic applications.
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5. Karthik  neduri  et  al.,  studied the  different  techniques  to  enhance  the
dissolution rate  of  lovastatin:  formulation and evaluation.   They studied
enhancement  of  the dissolution  profile,  absorption  efficiency  and
bioavailability of  water insoluble drugs like Lovastatin  by using various
techniques. Lovastatin is a poorly soluble, highly permeable drug and the
rate of its oral absorption is often controlled by the dissolution rate in the
gastrointestinal. They made an attempt to enhance the  in vitro dissolution
profile  of  Lovastatin  by  using  various  methods  like  solid  dispersions,
superdisintegrants and sublimation with respective to conventional drug.
6. Gande Suresh et al., studied whether the bioavailability of lovastatin could
be improved by administering lovastatin  solid  lipid  nanoparticles (SLN)
duodenally to rats. Lovastatin SLN were developed using triglycerides by
hot  homogenization  followed  by  ultrasonication.  Particle  size  and  zeta
potential  were  measured  by  photon  correlation  spectroscopy.
Bioavailability  studies  were  conducted  in  male  Wistar  rats  after
intraduodenal  administration  of  lovastatin  suspension  and  SLN.  Stable
lovastatin SLN had mean size range of 60 to 119 nm and a zeta potential
range of –16 to –21 mV. More than 99% of the lovastatin was entrapped in
the SLN. Lovastatin was dispersed in an amorphous state, and triglycerides
were  in  β1 form in  the  SLN. In vitro  stability studies  showed the  slow
release  and  stability  of  lovastatin  SLN.  The  relative  bioavailabilities  of
13
  
lovastatin and lovastatin hydroxy acid of SLN were increased by ~173%
and 324%, respectively, compared with the reference lovastatin suspension.
7. Pragati  et  al.,  reviewed  the  solid  lipid  nanoparticles  and  reported  the
advantages  of  solid  lipid  nanoparticles  delivery  system.  The  solid  lipid
nanoparticles are bioacceptable and    biocompatible in nature since less
toxic.  The  review  mainly  focused  on  preparation,  advantages,
characterization and special features.
8. Muller RH et al., reviewed the solid lipid nanoparticles and reported the
importance of the SLN in drug delivery. They have reported the ability of
the SLN to deliver the drug in controlled manner.
9. Seenivasan A et  al., reported  the  nano  drug  delivery system,  the  latest
technology employed in various  medicinal  applications.  This  technology
can  be  adapted  to  the  conventional  drug  administration  due  to  its  site-
specific targeting phenomena. The oral lipophilic drug administration has
its drawbacks due to poor solubility and bioavailability. Lipid-based carrier
systems are now widely popular due to improved efficiency, especially for
lovastatin delivery. Lovastatin is an important drug which arrests the rate-
limiting step of the cholesterol cascade. This drug has short half-lives, poor
oral-administered  bioavailability,  poor  solubility,  and  is  rapidly
metabolizable.  Based  on  the  composition,  the  drug  delivery carriers  are
14
  
classified into solid lipid nanoparticles (SLNs), lipid emulsions (LEs), and
nanostructured  lipid  carriers  (NLCs).  Among them,  NLCs are  a  smarter
generation of drug delivery carriers for lovastatin. The selection of various
lipid  systems  and  their  formulation  are  discussed.  Moreover,  the
characterization  of  these  carrier  systems  to  achieve  the  optimal
characteristic features is discussed in a concise manner. 
10. Eldem et al., studied the  importance of polymorphism occurring in solid
dosage forms causing instability, the polymorphic behavior of spray-dried
and -congealed lipid micropellets  was examined by differential  scanning
calorimetry and scanning electron microscopy. The results showed that both
of the spraying processes exert an important effect on their polymorphic
and  crystallization  properties.  In  spray-drying,  due  to  the  rapid  solvent
evaporation,  the  obtained  lipid  micropellets  possess  an  unstable
polymorphic form. This unstable form transforms gradually toward a stable
form by storage  at  elevated  temperatures.  The same modifications  were
observed  with  spray-congealed lipid  micropellets.  The type  of  glyceride
(composition,  chain  length),  solvent  and  drugs  (estradiol  cypionate,
medroxyprogesterone  acetate)  and,  further,  the  presence  of  a  stabilizing
agent such as lecithin affect the polymorphic transition and its rate.
15
  
11. Patricia Severino et al., reported the Lipids and lipid nanoparticles. These
have  been  exploited  for  many  features  in  the  field  of  pharmaceutical
technology. Lipids usually enhance drug absorption in the gastrointestinal
tract  (GIT),  and  when  formulated  as  nanoparticles,  these  molecules
improve mucosal adhesion due to small particle size and increasing their
GIT residence time. In addition,  lipid nanoparticles may also protect the
loaded  drugs  from  chemical  and  enzymatic  degradation  and  gradually
release  drug  molecules  from  the  lipid  matrix  into  blood,  resulting  in
improved therapeutic profiles compared to free drug. Therefore, due to their
physiological and biodegradable properties, lipid molecules may decrease
adverse side effects and chronic toxicity of the drug-delivery systems when
compared to other of polymeric nature. They highlighted the importance of
lipid nanoparticles to modify the release profile and the pharmacokinetic
parameters of drugs when administrated through oral route.
12. Wolfgang  Mehnert  et  al., studied  the  solid  lipid  nanoparticles  and  its
production,  characterization  and applications  in  pharmaceuticl  field.  The
reported the various methods for production of nanoparticles.
13. Mehnert  W  et  al., reported  the  solid  lipid  nanoparticles  production,
characterization.  They  also  reported  the  applications  of  solid  lipid
nanoparticles in various therapies. 
16
  
14. Mukherjee et al., studied and reported the solid lipid nanoparticles. The
results  concluded  the  solid  lipid  nanoparticles  are  used  as  modern
formulation approach in drug delivery system.  
15. Wissing et al., reported the solid lipid nanoparticles and their application in
the  pharmaceutical  field.  They  also  studied  the  use  of  SLN  when  its
delivered in parenteral route. 
16. Cortesi  et  al., evaluated  the  production  of  lipospheres.  The  lipospheres
formulated  by using  the  lipid  carriers  and  reported  their  use  to  deliver
deliver bioactive compounds.  
17. Rudolph et al., studied the application of novel solid lipid nanoparticles
(SLN)-gene  vector  formulations.  They  formulated  the  diametric  HIV-1
VAT-peptide and evaluated them in vitro and in vivo.  
18. Arunkumar. N et al., attempted to improve the solubility and dissolution
characteristics of a poorly soluble drug using nanosuspension technology.
Nanoparticles  were  characterized  in  terms  of  size  and  morphological
characteristics.  Saturation  solubility  and  dissolution  characteristics  were
investigated and compared to the commercial drug. Crystallinity of the drug
was  also  evaluated  by  performing  thermal  gravimetric  analysis  (TGA),
differential  scanning  calorimetry  (DSC)  and  powder  X-ray  diffraction
17
  
(PXRD) to denote eventual transformation to amorphous state during the
homogenization process. The study shown that the crystalline state of the
drug is reduced following particle size reduction and the dissolution rates of
amorphous  atorvastatin  calcium  nanoparticles  were  highly  increased  in
comparison  with  commercial  drug  by  the  enhancement  of  intrinsic
dissolution rate and the reduction of particle size, resulting in an increased
specific surface area.
19. Panakanti Gayatri et al., studied the formulation of Atorvastatin loaded
solid lipid nanoparticles by hot homogenization fallowed by ultrasonication
technique,  and  optimization  of  formulation  and  process  parameters  to
formulate preferred SLN dispersions. The effects of composition of lipid
materials, surfactant mixture and sonication time on particle size, PDI, zeta
potential,  drug entrapment  efficiency,  and in  vitro drug release  behavior
were  investigated.  The  mean  particles  size,  PDI,  zeta  potential  and
entrapment efficiency of optimized formulation (A5) was found to be 50.0±
6.12  nm,  0.08±0.011,10.40±  4.68mV,  88.7±  6.08  %  respectively.  To
characterize the state of drug and lipid modification in ATRS loaded solid
lipid  nanoparticles,  differential  scanning  calorimetry  analysis  was
performed.  Shape  and  surface  morphology  was  determined  by
Transmission Electron Microscopy (TEM) which revealed fairly spherical
shape of nanoparticles. The in-vitro drug release study demonstrated that
18
  
ATRS-SLN  formulation  (A5)  possessed  controlled  drug  release  over  a
period of 24 hrs than dispersion of pure drug.
20. Seenivasan et al., studied the oral lipophilic drug administration and its
drawbacks  due  to  poor  solubility  and  bioavailability.  Lovastatin  is  an
important  drug  which  arrests  the  rate-limiting  step  of  the  cholesterol
cascade.  This  drug  has  short  half-lives,  poor  oral-administered
bioavailability, poor solubility, and is rapidly metabolizable. Based on the
composition,  the  drug  delivery  carriers  are  classified  into  solid  lipid
nanoparticles  (SLNs),  lipid  emulsions  (LEs),  and  nanostructured  lipid
carriers  (NLCs).  Among  them,  NLCs  are  a  smarter  generation  of  drug
delivery carriers for lovastatin. The characterization of these carrier systems
to  achieve  the  optimal  characteristic  features  is  discussed  in  a  concise
manner.
21. Radha et al., reviewed the production of  lovastatin, while other statins like
rosuvastatin,  simvastatin,  pravastatin,  fluvastatin  are  synthesized  from
lovastatin and mevastatin. Other than reduction of cholesterol, lovastatin is
shown  to  provide  various  medicinal  properties  like  anti-cancer,  bone
maturation,  multiple  sclerosis.  This  review  discussed  production  of
lovastatin and different fermentation techniques. This review also helps in
understating the inhibition of HMG-CoA reducatse and various medicinal
properties of lovastatin.
19
  
22. Raja Rajeswari et al., attempted to improve the solubility and dissolution
rate using solid dispersion of a poorly soluble drug Lovastatin by using
Soluplus as carrier material to enhance the solubility as well as dissolution
rate.  Six  different  formulations  were  prepared  using  hot  melt  extrusion
technique in different ratios i.e., 1:1, 1:2, 1:3, 1:5, 1:7, and 1:9 and were
further  characterized  by  FTIR,  DSC,  and  SEM  analysis.  SEM  studies
showed  the  surface  morphology  of  the  solid  dispersion.  All  the
formulations showed a marked increase in drug release with the increase in
the  concentration  of  soluplus  when  tested  for  their  in  vitro  studies.
Formulation F6 showed the best release with a cumulative release of 99%
in 50 mins when compared to the pure drug, Physical mixture and marketed
formulation. Hence, soluplus look to be a promising carrier to improve the
solubility of poorly soluble drugs.
23. Shalini Asthana et al.,  A developed RP-HPLC method for the purpose of
analysis of antihypertensive: nifedipine (NF), antidiabetic: nateglinide (NG)
and hypolipidemic: lovastatin (LT) drugs simultaneously in cardiovascular
polypill  based  synthetic  ternary  mixture.  The  validated  method  was
successfully applied to the analysis of synthetic mixture of tablets of three
drugs; the percentage recoveries obtained were 100.23% for NF, 100.35%
for NG and 100.93% for LT.
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24. Karthik  neduri  et  al., studied  to  enhance  the  dissolution  profile,
absorption  efficiency  and  bioavailability  of  water  insoluble  drugs  like
Lovastatin  by  using  various  techniques.  Lovastatin  is  a  poorly  soluble,
highly permeable drug and the rate of its oral absorption is often controlled
by the dissolution rate in the gastrointestinal tractthe results suggest that
there was satisfactory dissolution enhancement from all three methods and
could potentially lead to improvement in bioavailability of oral lovastatin
products, but superdisintegrant method was preferred due to its simplicity,
low cost and industrial feasibility.
25. Manjil Patel et al., improved the solubility of poorly water soluble drug
lovastatin (LS) by solid dispersion (SD) techniques using modified locust
bean gum (MLBG) as a carrier. The locust bean gum (LBG) was modified
by heating and there observed irreversible decrease in viscosity, whereas
swelling property remains unaffected. Dissolution study revealed that the
modified solvent evaporation is most convenient and effective method for
solubility enhancement of  poorly water soluble  drug LS, among various
methods  of  preparation  of  SD.  The  prepared  SDs  was  characterized  by
differential scanning calorimetry, scanning electron microscopy, and X-ray
diffraction study. In vivo study was performed by measuring 3-hydroxy-3-
methyl-glutaryl-coenzyme  A (HMG  Co-A)  reductase  inhibition  activity.
Significant reduction in HMG Co-A reductase activity was observed in case
of solid dispersions of LS than plain LS.
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26. Xiao Gu., investigated  a  non-protein  nanostructured lipid  carrier  (NLC)
resembling  high-density  lipoprotein  (HDL)  could  deliver  a  hydrophobic
anti-atherogenic  drug,  lovastatin,  to  foam  cells.  Lovastatin-loaded  NLC
(LT-NLC) was prepared by a nanoprecipitation/solvent diffusion method.
The  LT-NLC-apoprotein  (LT-NLC-apo)  was  prepared  by  incubating  LT-
NLC  with  native  HDL.  The  results  indicated  that  non-protein  NLC
resembling HDL could be a useful tool to deliver lipophilic anti-atherogenic
drugs  to  foam cells,  and  that  uptake  could  be  enhanced  by the  VLDL
receptor pathway.
27. Faghfouri et  al.,  reported  the optimum  condition  for  solid  lipid
nanoparticles preparation. The method used to obtain nanoparticles with the
size of about 220 nm and PDI of about 0.25. The optimized set of method
variables  were  determined  and  validated  for  the  new  SLN  preparation
method.
28. Raksha  L.Mhetre.,  developed developed  controlled  release  SLNs  by
incorporating the drug in to lipid nanocarriers. The nanosize of particles
and lipid used for formulation would help to improve solubility of drug as
well as control drug release over prolonged period. SLNs were prepared by
High  shear  homogenization (HSH) technique using stearic  acid  as  solid
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lipid  core,  Tween  80  and  Poloxamer  188  as  stabilizers.  Palatability  of
nanodispersion was improved using sweetener and flavors. 
29. Makarand Gambhire et al., attempted to improve oral bioavailability of
simvastatin  by  incorporating  in  solid  lipid  nanoparticles  (SLN).  The
purpose of thie research was to study whether the oral bioavailability of
simvastatin could be improved by administering simvastatin loaded SLNs.
Simvastatin  SLNs  were  developed  using  compritol  888  ATO  by  pre-
emulsion  followed  by  ultrasonication  and  characterized  by  photon
correlation  spectroscopy,  DSC  and  XRD.  Bioavailability  studies  were
conducted in albino rats after oral administration of simvastatin suspension
and  SLN.  The  obtained  results  indicated  SLNs as  potential  carriers  for
improving  the  bioavailability  of  poorly  bioavailable  drugs  such  as
simvastatin by minimizing first pass metabolism.
AIM OF WORK
Presently,  many research  groups  are  trying to  explore  the  possibility  of
using solid lipid nanoparticles (SLN) as drug carriers. The concept of SLN was
first investigated a decade ago to unravel problems associated with other colloidal
drug  delivery  systems,  such  as  instability  and  non  biodegradability.  SLN  are
widely used to improve bioavailability and to achieve sustained release. 
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To overcome the drawbacks associated to the traditional colloidal systems
such  as  emulsions,  Liposomes,  and  polymeric  nanoparticles  solid  lipid
nanoparticles (SLN) have been developed. 
• SLN are biocompatible and biodegradable and have been used
for controlled drug delivery and specific targeting.
• These colloidal carriers consist of a lipid matrix that should be
solid  at  both  room and  body  temperatures,  having  a  mean
particle size between 50 nm and 1000nm.which are dispersed
in water or aqueous surfactant solution.
• They  are  made  up  of  solid  hydrophobic  core  having  a
monolayer  of  phospholipid  coating.  Solid  core  contains  the
drug dispersed or dissolved in lipid matrix. 
• They have potential to carry lipophilic or hydrophilic drugs. 
Lovastatin is a poorly soluble drug with a shorter half life of 1.1-1.7 h and
less  than  5%  bioavailability  so  an  attempt  was  to  formulate  solid  lipid
nanoparticles of lovastatin. Due to the following advantages of lipid based drug
delivery systems like solid lipid nano plarticles,
• Lipid-based drug delivery systems may contain a broad range of oils,
surfactants, and co-solvents. 
• They represent one of the most popular approaches to overcome the
absorption  barriers  and  to  improve  the  bioavailability  of  poorly
water-soluble drugs. 
• Furthermore, among the factors affecting the bioavailability of the
drug from lipid-based formulations  are  the  digestion  of  lipid,  the
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mean emulsion droplet diameter, the lipophilicity of the drug and the
type of lipids. 
• Lipid formulations can reduce the inherent limitation of slow and
incomplete dissolution of poorly water-soluble drugs and facilitate
formation of solubilized phases from which absorption may occur. 
• The  solubilized  phases  most  likely  arise  from  intral  aminal
processing after lipid absorption. 
• The  co-administration  of  lipids  with  drugs  can  also  impact  their
absorption pathway although most orally administered compounds
gain  access  to  the  systemic  circulation  via  the  portal  vein,  some
highly  lipophilic  drugs  are  transported  directly  to  the  systemic
circulation  via  intestinal  lymphatic’s,  which  improves  oral
bioavailability of poorly water soluble API like lovastatin.8
The aim of the current work is to formulate and evaluate the solid lipid
nanoparticles of lovastatin to deliver sustained drug release. Due to the lipid nature
of solid lipid nanoparticles of lovastatin the problems associated with conventional
formulations like poor  solubility and less  bioavailability can be improved in  a
reasonable manner.
Statins  are  compounds  of  natural  origin  that  are  biosynthesized  as
secondary  metabolites  of  several  filamentous  fungi  and  act  as  competitive
inhibitors of HMG-CoA reductase. They are bulky and literally get “stuck” in the
active site. This prevents the enzyme from binding with its substrate, HMG-CoA.
Today, there are two classes of statins: 
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• Natural  Statins: Lovastatin  (Mevacor),  Compactin,  Pravastatin
(Pravachol), Simvastatin (Zocor). 
• Synthetic Statins: Atorvastatin (Lipitor), Fluvastatin (Lescol). The
most common statins are atorvastatin (Lipitor), fluvastatin (Lescol),
lovastatin  (Mevacor,  Altocor),  pravastatin  (Pravachol),  simvastatin
(Zocor), and rosuvastatin (Crestor).
 Lovastatin,  a specific and potent competitive inhibitor  of  3-hydroxy- 3-
methyl  glutaryl  coenzyme  A  (HMG-CoA)  is  a  powerful  serum  cholesterol-
lowering drug in humans and other species. It  is formerly called as mevinolin;
monacolin K, and mevacor and it is a fungal secondary metabolite which inhibits
HMG-CoA reductase, the first committed enzyme of cholesterol biosynthesis. The
endogenous synthesis of cholesterol is carried out by the mevalonate pathway, in
which  the  rate  limiting  reaction  is  the  conversion  of  (S)  HMG-CoA to  (R)
mevalonate, catalyzed by HMG-CoA reductase. 
The history of statin began in 1987 when the lovastatin received Food and
Drug Administration (FDA) approval in the USA. Lovastatin have revolutionized
the  treatment  of  hypercholesterolemia  and  it  is  proven  that  lovastatin  is  also
therapeutically  and  preventatively  effective  in  the  treatment  of  major  kind  of
diseases like atherosclerosis, sepsis, peripheral arterial disease, peripheral vascular
disease, cerebro vascular disease, ischemic disease, and bone fracture.11
Lovastatin  lowers  cholesterol  levels  through  reversible  and  competitive
inhibition  of  3-hydroxy-  3-methylglutaryl  coenzyme  A reductase,  an  enzyme
26
  
involved in the biosynthesis  of  cholesterol.  It  exhibits  poor  oral  bioavailability
because of rapid metabolism in the gut and liver.  It’s a poorly soluble drug with a
shorter half life of 1.1-1.7 h and less than 5% bioavailability.12 Cytochrome P450
3A4  metabolizes  the  lactone  form  of  lovastatin  into  hydroxy  acid  and  its
metabolites.11
Lovastatin (whose water solubility is 0.4 × 10−3 mg/mL) is considered to
be a reasonable substrate for intestinal lymphatic transport because of its high log
P value  (4.3)  and  good  solubility  in  oils  (38  and  42  mg/mL in  carbitol  and
propylene glycol monocaprylate, respectively). 
The  solid  lipid  nanoparticles  of  lovastatin  would  be  an  alternate  to
conventional  formulations  by  providing  sustained  drug  release  and  improved
bioavailability due to improved solubility.
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PLAN OF WORK
1. Determination of max of lovastatin
2. Calibration curve for the drug in phosphate buffer pH 7.4
3. Drug polymer interaction study by using FTIR
4. Formulation of solid lipid nanoparticles of lovastatin by hot homogenization
technique by using different concentrations of surfactant.
5. Evaluation of particle size
6. Determination of percentage drug entrapment efficiency
7. Evaluation of in vitro drug release.
8. Comparisons of In –vitro release pattern of optimized solid lipid nanoparticles
of lovastatin with lovastatin pure drug solution.
9. Stability studies of optimized solid lipid nanoparticles of lovastatin.
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MATERIALS AND EQUIPMENTS
MATERIALS USED
1. Drug- Lovastatin                          - Cipla laboratories
2. Stearic acid                                         - Hospira laboratories
3. Poloxamer                                          -  Hospira laboratories
4. Tween 80                                                       - Ultra Chem laboratories
                                                     
5. Di-sodium hydrogen phosphate      - Vin biotech systems             
                                                                                      
6. Sodium hydroxide      - Nice chemicals
EQUIPMENTS USED
1. Homogenizer                                    - Bombay India ltd.
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2. Malvern zeta sizer                             - SM, UK.     
3. Electronic Balance           - A&D Company, Japan
4. Magnetic Stirrer           - MC Dalal & co 
5. UV Visible Spectrophotometer        - UV Pharma spec 1700, Shimadzu
6. FTIR Spectrophotometer                 - Perkin Elmer, Model - 78625.
7. Environmental chamber                   - Inlab equipments (Madras pvt ltd)
DRUG PROFILE
Lovastatin
Statins  are  compounds  of  natural  origin  that  are  biosynthesized  as
secondary  metabolites  of  several  filamentous  fungi  and  act  as  competitive
inhibitors of HMG-CoA reductase. They are bulky and literally get “stuck” in the
active site.
Structural formula
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IUPAC Name
(1S,3R,7S,8S,8aR)-8-{2-
[(2R,4R)-4- hydroxy-6-oxooxan-2-
yl]ethyl}-3,7-dimethyl- 1,2,3,7,8,8a-
hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
Properties:
Water solubility 0.0004 mg/mL
logP 4.11
logs                        -4.2
pKa (strongest acidic)   14.91
pKa (strongest basic)   -2.8
Physiological charge 0
Hydrogen acceptor count 3
Hydrogen donor count 1
Polar surface area                   72.83
Polarizability            46.11
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Melting point           174.5 °C
Dosing
The dose range for lovastatin is  10-80 mg daily given preferably in the
evening when it may be most effective. The usual starting dose is 20 mg once
daily, and the maximum dose is 80 mg daily. Blood cholesterol determinations are
performed at regular intervals during treatment so that adjustments in dosage can
be made.39
Protein binding
Lovastatin  and  its  β-hydroxyacid  metabolites  are  highly  protein  bound
(>95%).
Metabolism 
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Lovastatin is hepatically metabolized in which the major active metabolites
are the β-hydroxyacid of lovastatin, the 6’-hydroxy derivative, and two additional
metabolites (CYP3A substrate).
Route of elimination
Lovastatin undergoes extensive first-pass extraction in the liver, its primary
site of action, with subsequent excretion of drug equivalents in the bile. 83% of the
orally administered dose is excreted in bile and 10% is excreted in urine.
Bioavailability
<5%
Half-life
1.1-1.7 hours
Clearance
Not Available
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Pharmacodynamics
The  primary  cause  of  cardiovascular  disease  is  atherosclerotic  plaque
formation.  Sustained elevations of  cholesterol  in the  blood increase the risk of
cardiovascular  disease.  Lovastatin  lowers  hepatic  cholesterol  synthesis  by
competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-
limiting  step  in  the  cholesterol  biosynthesis  pathway  via  the  mevalonic  acid
pathway.  Decreased  hepatic  cholesterol  levels  causes  increased  uptake  of  low
density  lipoprotein  (LDL)  cholesterol  and  reduces  cholesterol  levels  in  the
circulation. At therapeutic doses, lovastatin decreases serum LDL cholesterol by
29-32%, increases high density lipoprotein (HDL) cholesterol by 4.6-7.3%, and
decrease  triglyceride  levels  by  2-12%.  HDL cholesterol  is  thought  to  confer
protective effects against CV disease, whereas high LDL and triglyceride levels
are associated with higher risk of disease. 40
Mechanism of action
Lovastatin  is  structurally  similar  to  the  HMG,  a  substituent  of  the
endogenous  substrate  of  HMG-CoA reductase.  Lovastatin  is  a  prodrug  that  is
activated in vivo via hydrolysis of the lactone ring to form the β-hydroxyacid. The
hydrolyzed  lactone  ring  mimics  the  tetrahedral  intermediate  produced  by  the
reductase allowing the agent to bind to HMG-CoA reductase with 20,000 times
greater affinity than its natural substrate. The bicyclic portion of lovastatin binds to
the coenzyme A portion of the active site.
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Absorption
Studies suggest that <5% of the oral dose reaches the general circulation as
active  inhibitors.  Time  to  peak  serum  concentration  is  2-4  hours.  Lovastatin
undergoes extensive first-pass metabolism so the availability of the drug in the
system is low and variable.
Volume of distribution
Lovastatin is able to cross the blood-brain-barrier and placenta.
Side effects
Lovastatin is usually well tolerated. As with all statin drugs, it can rarely
cause myopathy or rhabdomyolysis. This can be life-threatening if not recognised
and  treated  in  time,  so  any  unexplained  muscle  pain  or  weakness  whilst  on
lovastatin  should  be  promptly  mentioned  to  the  prescribing  doctor.  Other
uncommon  side  effects  that  should  be  promptly  mentioned  to  either  the
prescribing doctor or an emergency medical service include:
• Muscle pain, tenderness, or weakness
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• Lack of energy
• Weakness
• Fever
• Dark colored urine
• Jaundice: yellowing of the skin or eyes
• Pain in the upper right part of the stomach
• Nausea
• Unusual bleeding or bruising
• Loss of appetite
• Flu-like symptoms
• Rash
• Hives
• Itching
• Difficulty breathing or swallowing
• Swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower 
legs
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• Hoarseness
Indication
For management as an adjunct to diet to reduce elevated total-C, LDL-C,
apo B, and TG levels in patients with primary hypercholesterolemia and mixed
dyslipidemia. It is also used for primary prevention of coronary heart disease and
to slow progression of  coronary atherosclerosis  in patients with  coronary heart
disease.
Uses
 Lovastatin is  used  along  with  a  proper  diet  to  help  lower
"bad"cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol
(HDL) in the blood. It belongs to a group of drugs known as "statins." It works by
reducing the amount of cholesterol made by the liver. Lowering "bad" cholesterol
and  triglycerides  and  raising  "good"  cholesterol  decreases  the  risk  of heart
disease and helps prevent strokes and heart attacks.In addition to eating a proper
diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help
this medication work better include exercising, losing weight if overweight, and
stopping smoking. Consult your doctor for more details.
Storage
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Immediate  release  tablets  should  be  stored  between  5-300 C  (41-86  F).
Extended release tablets should be stored at room temperature, 20-250 C (68-77 F).
41
EXCIPIENTS PROFILE
Poloxamer
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Nonproprietary Names
Poloxamers
Synonyms
Lutrol;  Monolan;  Pluronic;  poloxalkol;  poloxamera;  polyethylene–
propylene  glycol  copolymer;  polyoxyethylene–polyoxypropylene  copolymer;
Supronic; Synperonic.
Chemical Name and CAS Registry Number
a-Hydro-o-hydroxypoly(oxyethylene)poly(oxypropylene)  poly-  (oxyethylene)
block copolymer [9003-11-6]
Empirical Formula and Molecular Weight
The poloxamer polyols are a series of closely related block copolymers of
ethylene  oxide  and  propylene  oxide  conforming  to  the  general  formula
HO(C2H4O)a(C3H6O)b(C2H4O)aH. 
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Functional Category
It is used as dispersing agent, emulsifying agent, solubilizing agent, tablet
lubricant and wetting agent.
Structural Formula
Applications in Pharmaceutical Formulation or Technology
Poloxamers  are  nonionic  polyoxyethylene–polyoxypropylene  copolymers
used  primarily  in  pharmaceutical  formulations  as  emulsifying  or  solubilizing
agents. The polyoxyethylene segment is hydrophilic while the polyoxypropylene
segment  is  hydrophobic.  All  of  the  poloxamers  are  chemically  similar  in
composition,  differing  only in  the  relative  amounts  of  propylene  and  ethylene
oxides  added  during  manufacture.  Their  physical  and  surface-active  properties
vary  over  a  wide  range  and  a  number  of  different  types  are  commercially
available. Poloxamers are used as emulsifying agents in intravenous fat emulsions,
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and as solubilizing and stabilizing agents to maintain the clarity of  elixirs  and
syrups.
 Poloxamers may also be used as wetting agents; in ointments, suppository
bases, and gels; and as tablet binders and coatings. Poloxamer 188 has also been
used as an emulsifying agent for fluorocarbons used as artificial blood substitutes,
and  in  the  preparation  of  solid-dispersion  systems.  More  recently,  poloxamers
have found use in drug-delivery systems. 
Therapeutically, poloxamer 188 is administered orally as a wetting agent
and  stool  lubricant  in  the  treatment  of  constipation;  it  is  usually  used  in
combination  with  a  laxative  such  as  danthron.  Poloxamers  may  also  be  used
therapeutically as  wetting agents  in  eye-drop formulations,  in  the  treatment  of
kidney stones, and as skin-wound cleansers. Poloxamer 338 and 407 are used in
solutions for contact lens care. 
S.No Uses Concentration (%)
1. Fat emulsifier 0.3
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2. Flavor solubilizer 0.3
3. Fluorocarbon emulsifier 2.5
4. Gelling agent 15–50
5. Spreading agent 1
6. Stabilizing agent 1–5
7. Suppository base 4–6 or 90
8. Tablet coating 10
9. Tablet excipient 5–10
10. Wetting agent 0.01–5
Description
Poloxamers generally occur as white, waxy, free-flowing prilled granules,
or as cast solids. They are practically odorless and tasteless. At room temperature,
poloxamer 124 occurs as a colorless liquid.
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 Typical Properties
Acidity/alkalinity  pH = 5.0–7.4 for a 2.5% w/v aqueous solution.
Cloud point >1000C for a 1% w/v aqueous solution, and a
10%              aqueous solution of poloxamer 188.
Density  1.06 g/cm3 at 250C
Flash point  2600C
Flowability Solid poloxamers are free flowing.
HLB value 0.5–30; 29 for poloxamer 188.
Melting point
It is 52–570C for poloxamer 188.
Moisture content 
Poloxamers  generally  contain  less  than  0.5%  w/w  water  and  are
hygroscopic only at relative humidity greater than 80%. 
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Solubility
 Solubility varies according to the poloxamer type.
Surface tension
19.8mN/m  (19.8  dynes/cm)  for  a  0.1%  w/v  aqueous  poloxamer  188
solution at 250C;
24.0mN/m  (24.0  dynes/cm)  for  a  0.01%  w/v  aqueous  poloxamer  188
solution at 250C;
26.0mN/m (26.0 dynes/cm) for a 0.001% w/v aqueous poloxamer solution
at 250C.
Viscosity (dynamic)
 1000 mPa s (1000 cP) as a melt at 770C for poloxamer 188.
Stability and Storage Conditions
Poloxamers  are  stable  materials.  Aqueous  solutions  are  stable  in  the
presence of acids,  alkalis,  and metal  ions.  However,  aqueous solutions  support
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mold growth. The bulk material should be stored in a well-closed container in a
cool, dry place.
Incompatibilities
Depending on the relative concentrations, poloxamer 188 is incompatible
with phenols and parabens. 42, 43
Polysorbate 80
Synonyms 
Polysorbate  80,  Polyoxyethylene  Sorbitan  Monooleate,  Monitan,
Ethoxylated  Sorbitan  Monooleate,  Sorbital  O  20,  Sorlate,  Polyethylene  glycol
sorbitan monooleate
Product information
It’s  a  nonionic  surfactant and emulsifier derived
from polyethoxylated sorbitan and oleic  acid,  and  is  often  used  in  foods.
Polysorbate 80 is a viscous, water-soluble yellow liquid. The hydrophilic groups in
this compound are polyethers also known as polyoxyethylene groups which are
polymers  ofethylene  oxide.  In  the  nomenclature  of  polysorbates,  the  numeric
designation following polysorbate refers to the lipophilic group, in this case the
oleic acid (see polysorbate for more detail). Polysorbate 80 is often used in food
and other products as an emulsifier.
Molecular Formula
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 C32H60O10   
Molecular Weight
 604.8128 
IUPAC Name: 
2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-
hydroxyethoxy)ethoxy]ethyl(E)-octadec-9-enoate
Structural Formula
Product Description
Tween  80  is  a  polyethylene  sorbitol  ester,  non  ionic  surfactant  and  an
emulsifier derived from polyethoxylated sorbitan and oleic acid.
Molar mass             1310 g/mol
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Appearance Amber colored viscous liquid
Density 1.06–1.09 g/mL, oily liquid
Boiling point  > 100°C
Solubility in water Very soluble
Solubility in other solvents Soluble  in  ethanol,  cottonseed  oil,  corn  oil,  ethyl
acetate, methanol,  toluene
Applications
Tween  80  has  been  widely  used  in  biochemical  applications  including:
solubilizing proteins, isolating nuclei from cells in culture, growing of tubercule
bacilli, and emulsifying and dispersing substances in medicinal and food products.
It has little or no activity as an anti-bacterial agent. It has been shown to have an
adverse  effect  on  the  antibacterial  effect  of  methyl  paraben  and  related
compounds. 44,45
Stearic acid
Synonyms
Acidum  stearicum,  cetylacetic  acid,  Crodacid,  Cristal  G,  Cristal  S,
Dervacid,  E570,  Edenor,  Emersol,  Extra  AS,  Extra  P,  Extra  S,  Extra  ST,  1-
heptadecanecarboxylic  acid,  Hystrene,  Industrene,  Kortacid  1895,  Pearl  Steric,
Pristerene, stereophanic acid and Tegostearic.
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Empirical Formula and Molecular Weight
C18H36O2 284.47 (for pure material) The USP32–NF27 describes stearic
acid as a mixture of stearic acid (C18H36O2) and palmitic acid (C16H32O2). In
the USP32– NF27, the content of stearic acid is not less than 40.0% and the sum
of the two acids is not less than 90.0%. 
Structural Formula
Functional Category
Emulsifying agent, solubilizing agent, tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Stearic acid is widely used in oral and topical pharmaceutical formulations.
It is mainly used in oral formulations as a tablet and capsule lubricant; although it
may also be used as a binder or in combination with shellac as a tablet coating. It
has also been suggested that stearic acid may be used in enteric tablet coatings and
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as a sustained-release drug carrier. In topical formulations, stearic acid is used as
an emulsifying and solubilizing agent. When partially neutralized with alkalis or
tri-ethanolamine, stearic acid is used in the preparation of creams. The partially
neutralized stearic acid forms a creamy base when mixed with 5–15 times its own
weight  of  aqueous  liquid,  the  appearance  and  plasticity  of  the  cream  being
determined by the proportion of alkali used. Stearic acid is used as the hardening
agent in glycerin suppositories. Stearic acid is also widely used in cosmetics and
food products.
Description
Stearic acid is a hard,  white or faintly yellow-colored, somewhat glossy,
crystalline solid or a white or yellowish white powder. It has a slight odor and taste
suggesting tallow.
Typical Properties
Acid value 195–212
Boiling point 383oC
Density (bulk) 0.537 g/cm3
Density (tapped)  0.571 g/cm3
Density (true) 0.980 g/cm3
Flash point 1130C (closed cup)
Melting point 69–700C
Moisture content contains practically no water.
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Partition coefficient Log  (oil: water) = 8.2
Refractive index 1.43 at 800C
Saponification value 200–220
Solubility 
It is freely soluble in benzene, carbon tetrachloride, chloroform, and ether.
It’s  also  soluble  in  ethanol  (95%),  hexane,  and  propylene  glycol;  practically
insoluble in water.
Specific surface area
0.51–0.53m2/g 46, 47, 48
EXPERIMENTAL METHODS
    
CALIBRATION CURVE FOR LOVASTATIN
 PREPARATION OF CALIBRATION MEDIUM     
27.218 gm of potassium-di-hydrogen phosphate
 
was dissolved in sufficient
amount  of  distilled water  to  make  1000ml  of  0.2M solution.  8  gm of  sodium
hydroxide  was  dissolved  in  sufficient  amount  of  distilled  water  to  make  one
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1000ml  of  0.2M  solution.  From  the  above  solutions  50ml  of  potassium-di-
hydrogen  phosphate  solution and 22.4  ml  of  sodium hydroxide solutions  were
mixed and made up to 200ml with distilled water to get phosphate buffer solution
of pH 6.8. 
Preparation of standard curve for valsartan
 The standard stock solution of  lovastatin  was prepared by dissolving a
known amount of drug in small quantity of phosphate buffer pH 6.8. From the
above stock solution, different concentrations of 10, 20......50λg /ml was prepared
in same solution of phosphate buffer pH 6.8. The resulting solution was scanned in
UV Spectrophotometer to find  mmax and the absorbance was measured at  λmax
(239nm). The standard curve was plotted by taking concentration in X-axis and
absorbance in Y-axis. The standard curve was used to estimate drug content and
percentage drug release. 49, 50
FORMULATION  OF  LOVASTATIN  CONTAINING  SOLID  LIPID
NANOPARTICLES BY HOT HOMOGENIZATION TECHNIQUE: 
Drug-polymer compatibility study51  
Drug-polymer compatibility study was carried out by FTIR (ATR). Spectra
were recorded for pure drug, lipid and surfactant physical mixture. The spectrum
recorded by grinding and dispersing the samples with micronized IR grade KBr
powder.
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Formulation of Lovastatin SLNs
The  solid  lipid  nanoparticles  of  lovastatin  were  prepared  by  hot
homogenization technique and there were nearly six formulations formulated with
different concentrations of lipid, surfactant and stabilizer.
Solid  Lipid  Nanoparticles  of  Ibuprofen  were  produced  using  the  lipid
Stearic acid. The surfactant used for the formulation of SLN was Poloxamer 188
and  stabilizer  was  Tween-80  in  different  proportions.  The  formulations  were
prepared  by hot  homogenization  technique  using  the  high  speed  homogenizer.
The organic phase was prepared by dissolving the drug and surfactant in acetone:
ethanol  and  mixing  it  with  the  melted  stearic  acid,  Organic  solvents  were
completely removed using a Buchi rotoevaporator. The drug-embedded lipid layer
was melted by heating. The aqueous phase was prepared by mixing Tween-80 in
water. The aqueous and organic phase was maintained at the same temperature.
Then the organic phase was poured into aqueous Tween-80 solution. The various
concentrations  of  Tween-80  which  acts  as  a  stabilizer  and  stirred  with
homogenizer  on  water  bath  at  10,000  rpm for  10  minutes  by maintaining  the
temperature to 700c. The formulation was then removed from water bath and the
dispersion of SLN was mixed gently by slow magnetic stirring for I hour at room
temperature until cooling. 52, 53, 54 The formulation of SLN shown in table no: 1.
Table No: 1. Formulation of solid lipid nanoparticles of Lovastatin
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Formulation
Codes
Drug
Lovastatin
(mg)
Lipid
Stearic
acid
(%w/v)
Surfactant
Poloxamer
188
(%w/v)
Acetone:
Ethanol
(ml)
Water
 (ml)
Stabilizer
Tween 80
(ml)
F1 40 0.5 0.5 10 100 0.5
F2 40 1.0 1.0 10 100 1.0
F3 40 1.5 1.5 10 100 1.5
F4 40 1.0 1.5 10 100 2.0
F5 40 1.0 1.5 10 100 1.5
Physicochemical properties 
The  solid  lipid  nanoparticles  were  characterized  for  physicochemical
properties such as color, odor, pH, and taste.
Drug-polymer compatibility study
Drug-polymer compatibility study was carried out by FTIR (ATR). Spectra
were recorded for pure drug, polymer and for drug and polymer physical mixture.
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The FTI-IR spectrum pure drug sample and pure polymer sample with formulation
were  recorded  to  find  out  whether  any  interaction  of  drug  with  polymer  was
present in formulations.
Particle size and size distribution
Particle  size analysis  of  the selected  solid  lipid  nanoparticle  formulation
was performed using Malvern Mastersizer 2000. 
Scanning Electron Microscopy (SEM)
The particle size of the Nanoparticles was evaluated by Scanning Electron
Microscope  (SEM)  to  find  out  the  size  of  the  nanoparticles  and  to  study  the
surface morphology of the nanoparticles. Dried particles were taken in a piece of
black tape and attached to the sample holder. Particle morphology was determined
under  low vacuum.  The  SEM  method  provides  a  finest  approach  to  find  out
particles size and surface morphology when compared to other methods. 57,58
Drug Entrapment Efficiency
The  drug  entrapment  efficiency  of  the  formulations  was  calculated  by
centrifugation  of  the  aqueous  suspension.  The  amount  of  the  free  drug  was
detected in the supernatant and the amount of incorporated drug was determined as
the result of the initial drug minus the free drug. The percentage of incorporated
drug called entrapment efficiency was determined spectrophotometrically at 238
nm. 10,59 The entrapment efficiency was calculated by using the following formula:
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Entrapment efficiency EE (%) =   Wt of initial drug – Wt of free drug
              Wt of initial drug
In-vitro drug release study
The in vitro drug release was carried out by using diffusion studies by using
magnetic stirrer. The release of Ibuprofen from the solid lipid nanoparticles was
compared with the pure drug using a dialysis system comprising of a HiMedia
Dialysis Membrane-70. The dialysis membrane was filled with 2 ml of solid lipid
nanoparticles, and then the sample filled dialysis bags were tied and exposed to
diffusion medium containing Phosphate buffer pH (6.8). The medium was stirred
magnetically. The medium was maintained at a constant temperature of 37°C ±
0.5°C.  Aliquots  of  5ml  samples  were  drawn  at  specified  time  intervals.  The
samples were analyzed by using a UV spectrophotometer at 238 nm. 10,60
Stability Testing Studies
The  stability  study  for  the  optimized  formulation  was  performed  for  3
months according to the ICH Guidelines. The SLN of Ibuprofen was kept at 30 °C
± 2  °C  and  65% ± 5  % Relative  humidity  in  stability  chamber.  Particle  size
measurement, Drug entrapment was evaluated. 61,62
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RESULTS AND DISCUSSION                             
CALIBRATION CURVE OF VALSARTAN
            Calibration curve of lovastatin was done in phosphate buffer pH-6.8.
Lovastatin shows λmax of 238 nm in phosphate buffer pH-6.8. The correlation
coefficient  was  0.999.  Hence,  lovastatin  obeys  the  beer’s  law  within  the
concentration  range  of  10  to  50µg/ml.  The  calibration  plots  of  lovastatin  in
phosphate buffer pH-6.8 was showed in fig.2 and maximum absorbance showed in
fig.3 
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FORMULATION  OF  LOVASTATIN  CONTAINING  SOLID  LIPID
NANOPARTICLES BY HOT HOMOGENIZATION TECHNIQUE: 
            Five formulations of lovastatin as solid lipid nanoparticles were prepared
by using various  concentrations  of  lipid,  surfactant  and stabilizer  by using hot
homogenization  technique.  The  drug  concentration  kept  as  constant  for  each
formulation (40mg).
The main reason for selection of the method was to improve the solubility
of the poorly soluble drug by solid lipid nanoparticles and to improve the drug
release pattern of lovastatin nanoparticles to show the sustained release of drug.
The  improved  solubility  and  drug  release  leading  to  improvement  of
bioavailability of lovastatin.       
                              
EVALUATION OF FORMULATION
Drug-polymer compatibility study
FT-IR spectra of pure drug lovastatin, lipid and stabilizer and combination
of physical mixture were evaluated. The figures are shown in Fig 4, Fig 5 and in
Fig 6.  From the obtained spectra it was observed that all the characteristics peaks
of  lovastatin  were  present  in  the  combination  spectra  thus  indicating  the
compatibility of the drug with the lipid used. It shows that there was no significant
change in the chemical integrity of the drug.
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Physicochemical properties
The  solid  lipid  nanoparticles  were  characterized  for  physicochemical
properties such as color, odor, pH, and taste.
Characterization of nanoparticles for particle size analysis
The particle size analysis of the nanoparticles reveals that the particle sizes
were ranges from 80 – 250 nm and the particles were in nanometer size range. The
SEM 
Measurement of particle size and PDI
The particle size and PDI was found in range of 80.15 – 250.03 nm and
0.153  -  0.251  respectively  for  the  SLN.  The  SLNs  were  found  be  within
nanometer size range and it shows that increase in the concentration of both the
surfactant and stabilizer leads to decrease in particle size whereas increase in lipid
concentration  leads  to  increase  in  particle  size.  The  optimum concentration  of
surfactant and stabilizer was fixed as 1 % w/v. The Values were shown in Table.2,
Fig 7 and in Fig 8.
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Determination of percentage of drug entrapment efficiency
The drug entrapment efficiency was ranges from 75.76 % - 92.18 % of
lovastatin  SLNs  and  it  shows  the  increase  in  concentration  of  lipid  leads  to
increase in entrapment efficiency. The Values were shown in Table.2 and in Fig 9.
Determination of zeta potential
Zeta potential of the lovastatin SLNs nanoparticles was found in the range
of   -16.2±2.0  to  -28.6±0.7mV.  The  results  of  Zeta  potential  revealed  that  all
formulations were found stable. The Values were shown in Table.2.
Evaluation of In vitro drug release
The In-vitro drug release studies were carried out by using dialysis bag. The
data of  cumulative percentage drug release  of  the formulations were shown in
Table.3,  and in  Fig  10.  The  cumulative  percentage drug  release  after  8  h  was
studied
The percentage drug release lovastatin SLNs ranges from 52.20 – 80.62%
at  the  end  of  8  hrs.  Among  all  the  formulation  the  F3  which  contains  high
concentration of surfactant and stabilizer (1.5%w/v) with optimum particle size
shows 74.11% of drug release at the end of 8 hrs. The other two formulations with
same concentration of surfactant and lipid (1.5% w/v) with higher concentration of
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stabilizer  also show increase in drug release.  Based on the higher drug release
compared to lovastatin plain solution and optimum particle size, the F3 considered
as  best  formulation  for  further  evaluation.  The  comparison  of  in  vitro release
profile of F3 and lovastatin drug solution was shown in Fig 11.
Stability studies
Stability studies were carried out to find out the stability and changes in
appearance  and  entrapment  efficiency  for  optimized  formulation  F3.  The
formulation was stored at 30±2°C/65±5% RH for three months. The results were
shown Table 4.  The results  showed that  there was no significant  difference in
appearance and entrapment efficiency. 
SUMMARY 
• The purpose of this research was to develop novel solid lipid nanoparticles
of lovastatin drug delivery system to improve the poor solubility and poor
bioavailability of the drug.
• The novel solid lipid nanoparticles drug delivery system of lovastatin was
prepared by using stearic acid as lipid, poloxamer 188 as surfactant and
tween 80 as stabilizer by hot homogenization technique. 
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• Lovastatin used in the treatment of lowering cholesterol was successfully
formulated in solid lipid nanoparticles.
• The formulated solid lipid nanoparticles of lovastatin was   evaluated for
physicochemical  properties,  Particle  size  and  size  distribution,  Drug-
polymer  compatibility  study,  SEM,  percentage  of  drug  entrapment
efficiency, zeta potential, in vitro drug release, Stability studies.
• The  solid  lipid  nanoparticles  were  characterized  for  physicochemical
properties such as color, odor, pH, and taste.
• The particle size analysis of the nanoparticles reveals that the particle sizes
were ranges from 80 – 250 nm and the particles were in nanometer size
range. 
• The particle size and PDI was found in range of 80.15 – 250.03 nm and
0.153 - 0.251 respectively for the SLN.
• The drug entrapment efficiency was ranges from 75.76 % - 92.18 % of
lovastatin SLNs and it shows the increase in concentration of lipid leads to
increase in entrapment efficiency.
• Zeta potential of the lovastatin SLNs nanoparticles was found in the range
of  -16.2±2.0 to -28.6±0.7mV. The results of Zeta potential revealed that all
formulations were found stable. 
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• The percentage drug release lovastatin SLNs ranges from 52.20 – 80.62%
at the end of 8 hrs. 
• Among all  the formulation the F3 which contains high concentration of
surfactant  and  stabilizer  (1.5%w/v)  with  optimum  particle  size  shows
74.11% of drug release at the end of 8 hrs. 
• The other two formulations with same concentration of surfactant and lipid
(1.5% w/v) with higher concentration of stabilizer also show increase in
drug release.
• Based on the higher drug release compared to lovastatin plain solution and
optimum particle  size,  the  F3  considered as best  formulation for further
evaluation.
• Stability studies were carried out to find out the stability and changes in
appearance and entrapment efficiency for optimized formulation F3. The
formulation was stored at 30±2°C/65±5% RH for three months. 
CONCLUSION
• The results showed that there was no significant difference in appearance
and entrapment efficiency. 
• The  FTIR  results  proved  that  there  was  no  significant  change  in  the
chemical  integrity of the drug and no interactions between the drug and
polymers of lovastatin SLN.
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• The methodology adopted for the improvement of poor solubility and poor
bioavailability of the drug lovastatin solid lipid nanoparticles was effective.
• The  lovastatin  solid  lipid  nanoparticle  system  afforded  sustained  drug
release over 8-h period of time.
• Lipid-based drug delivery systems like lovastatin solid lipid nanoparticles
may contain a broad range of oils, surfactants, and co-solvents. 
• They  represent  one  of  the  most  popular  approaches  to  overcome  the
absorption  barriers  and  to  improve  the  bioavailability  of  poorly  water-
soluble drugs. 
• The Solid lipid nanoparticle formulations can reduce the inherent limitation
of  slow  and  incomplete  dissolution  of  poorly  water-soluble  drugs  and
facilitate formation of solubilized phases from which absorption may occur.
• The co-administration of lipids with drugs can also impact their absorption
pathway although most orally administered compounds gain access to the
systemic circulation via the portal vein, some highly lipophilic drugs are
transported directly to the systemic circulation via intestinal lymphatic’s,
which  improves  oral  bioavailability  of  poorly  water  soluble  API  like
lovastatin.
• The solid lipid nanoparticles of lovastatin formulation can be effective in
treatment  of  lowering  cholesterol  and  the  drug  was  released  from  the
formulation in a constant manner for the desired period of time.
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• The solid lipid nanoparticles of lovastatin evaluated here has potential in
reduction  of  cholesterol,  for  the  reason  that  improved  solubility  can
improve  the  bioavailability  of  the  poorly  soluble  drug  lovastatin  and
considered to be promising for prolonging the release of drug compared
with other conventional formulations.
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